- Home
- DOCS vs QGEN Comparison
DOCS vs QGEN Comparison
Compare DOCS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCS | QGEN |
|---|---|---|
| Founded | 2010 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | 5700 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.2B |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DOCS | QGEN |
|---|---|---|
| Price | $46.10 | $47.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 7 |
| Target Price | ★ $68.05 | $50.68 |
| AVG Volume (30 Days) | ★ 2.7M | 1.2M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | 42.88 | ★ 331.20 |
| EPS | 1.25 | ★ 1.84 |
| Revenue | $621,329,000.00 | ★ $2,070,781,000.00 |
| Revenue This Year | $15.22 | $7.12 |
| Revenue Next Year | $11.03 | $6.13 |
| P/E Ratio | $36.78 | ★ $25.56 |
| Revenue Growth | ★ 20.21 | 5.32 |
| 52 Week Low | $45.29 | $37.63 |
| 52 Week High | $85.21 | $51.88 |
Technical Indicators
Market Signals| Indicator | DOCS | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 28.80 | 55.46 |
| Support Level | $50.10 | $46.39 |
| Resistance Level | $51.80 | $48.13 |
| Average True Range (ATR) | 2.18 | 0.67 |
| MACD | 0.49 | 0.18 |
| Stochastic Oscillator | 9.53 | 68.53 |
Price Performance
Historical ComparisonAbout DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).